Fabiani et al. examined ocular flare rates in 37 patients with non-infectious uveitis pre- and post-switch from a variety of anti-TNFa bio-originators to their respective biosimilars.13 They found no statistically significant difference in the 12 months following switching. This evidence concerns the gene TNF and uveitis.